Indications and results of exclusive radiotherapy in early prostate adenocarcinoma;Indications et resultats de la radiotherapie exclusive dans les formes precoces d'adenocarcinome prostatique

Cancer/Radiotherapie

Volumn 1, Issue 5, 1997, Pages 431-438

  Bey, P ^a  

^a CENTRE ALEXIS VAUTRIN   (France)

Author keywords

Brachytherapy; Conformal radiation therapy; Exclusive radiation therapy; Localized prostate adenocarcinoma

Indexed keywords

ADULT; AGED; BRACHYTHERAPY; CANCER INCIDENCE; CANCER RADIOTHERAPY; CONFERENCE PAPER; EARLY DIAGNOSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; PELVIS LYMPH NODE; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; REMISSION; TUMOR LOCALIZATION; ADENOCARCINOMA; CANCER STAGING; MORTALITY; PATHOLOGY; PROSTATE TUMOR; RADIATION ACCIDENT; RADIATION DOSE; RADIATION INJURY; REVIEW; SURVIVAL; TREATMENT OUTCOME; TUMOR RECURRENCE;

ACCIDENTS, RADIATION; ADENOCARCINOMA; HUMANS; MALE; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROSTATIC NEOPLASMS; RADIATION INJURIES; RADIOTHERAPY DOSAGE; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0031451772     PISSN: 12783218     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1278-3218(97)89564-9     Document Type: Conference Paper

References (49)

1. D'Amico AV, Whittington R, Kaplan I, Beard C, Jiroutek M, Malkowicz SB et al. Equivalent biochemical failure - free survival after external beam radiation therapy or radical prostatectomy in patients with a pretreatment prostate specific antigen of > 4-20 ng/mL. Int J Radiat Oncol Biol Phys 1997;37: 1053-8
2. Asbell SO, Krall JM, Pilepich MV, Baerwald H, Sause WT, Hanks GE et al. Elective pelvic irradiation in stage A2, B carcinoma of the prostate: analysis of RTOG 77-06. Int J Radiat Oncol Biol Phys 1988;15:1307-16
3. Astro consensus panel. Consensus statement: guidelines for PSA following radiation therapy. Int J Radiat Oncol Biol Phys 1997;37:1035
4. Bagshaw MA, Kaplan ID, Cox RC. Radiation therapy for localized disease. Proceedings of the American Cancer Society National Conference on Prostate Cancer. Cancer 1993;71(suppl): 939-52
5. Blasko JC, Ragde H, Luse RW, Sylvester JE, Cavanag W, Grimm PD. Should brachytherapy be considered a therapeutic option in localized prostate cancer. Urolog Clin North Am 1996;23:633-50
6. Bolla M, Gonzalez D, Warde P, Dubois JB, Mirimanoff RO, Storme G et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engt J Med 1997;337:295-300
7. Bonin SR, Hanlon AL, Lee WR, Movsas B, Al-Saleem TI, Hanks GE. Evidence of increased failure in the treatment of prostate carcinoma patients who have perineural invasion treated with three-dimensional conformai radiation therapy. Cancer 1997:79:75-80
8. Borghede G, Hedelin H. Radiotherapy of localized prostate cancer. Analysis of late treatment complications. A prospective study. Radiother Oncol 1997;43:139-46
9. Bostwick DG, Myers RP, Oesterling JE. Staging of prostate cancer. Semin Surg Oncol 1994; 10:60-72
10. Brune D, Couette JE, Lesaunier F, Benabib D, Mace-Lesec'h J, Henry-Amar M. Combined external beam therapy (EBT) and brachytherapy in the treatment of localized prostate carcinoma: the 1979-1993 centre François-Baclesse experience [Abstract]. Radiother Oncol 1996;39(suppl 1):S2
11. Chauvet B, Jacob T, Davin JL, Berger C, Vincent P, Reboul F. Prostate specific antigen (PSA) : impact d'un marqueur sérique sur la prise en charge diagnostique et thérapeutique des cancers de prostate. Bull Cancer/Radiother\996;83-334
12. Diaz A, Roach M, Marquez C, Coleman L, Pickett B, Wolfe JS et al. Indications for and the significance of seminal vesicle irradiation during 3D conformai radiotherapy for localizad prostate cancer. Inl J Radiat Oncol Biol Phys 1994;30:323-9
13. Douchez J, Allain YM, Cellier P, Fenton J, Fregevu Y, Hay M et al. Cancer de la prostate: intolérance et morbidité de la radiothérapie externe. Bull Cancer 1985;72:573-7
14. Epstein JI, Carmichael M, Walsh PC. Carcinoma of the prostate invading the seminal vesicle: definition and relation of tumor volume, grade and margins of resection to prognosis. J Urol 1993:149:1040-5
15. Fleming C, Wasson J, Albertson PC, Barry MJ, Wennberg JE. A decision analysis of alternative treatment strategies for clinically localized prostate cancer. JAMA 1993:269:2650-8
16. Freedman GM, Hanlon AL, Lee WR, Hanks GE. Young patients with prostate cancer have an outcome justifying their treatment with external beam radiation. Int J Radiat Oncol Biol Phys 1996:35:243-50
17. Fuks Z, Leibel SA, Wallner KE, Begg CB, Fair WR, Anderson LL et al. The effect of local control on metastatic dissemination in carcinoma of the prostate: long-term results in patients treated with 1251 implantation. Int J Radiat Oncol Biol Phys 1991:21:537-47
18. Goluboff ET, Benson MC. External beam radiation therapy does not offer long-term control of prostate cancer. Urol Clin North Am 1996;23:617-21
19. Hanks GE. Optimizing the radiation treatment and outcome of prostate cancer. Int J Radiat Oncol Biol Phys 1985; 11:1235-45
20. Hanks GE. Long-term control of prostate cancer with radiation. Past, present and future. Urol Clin North Am 1996; 23:605-16
21. Hanks GE, Krall JM, Hanlon AL, Asbell SO. Pilepich MV, Owen JB. Patterns of care and RTOG studies in prostate cancer: long-term survival, hazard rate observations and possibility of cure. lut J Radiat Oncol Biol Phys 1993;28:39-45
22. Hanks GE, Hanlon AL, Hudes G, Lee WR, Suasin W, Schultheiss TE. Patterns-of-failure analysis of patients with high pretreatment prostate-specific-antigen levels treated by radiation therapy: the need for improved systemic ans locoregional treatment. J Clin Oncol 1996;14:1093-7
23. Hanks GE, Schultheiss TE, Hanlon AL, Hunt M, Lee WR, Epstein BE et al. Dose escalation in the conformai treatment of prostate cancer optimization is made possible by understanding the dose responses for control of cancer and late morbidity [Abstract]. Int J Radiat Oncol Biol Phys 1996; 36(suppl):197
24. Kaplan ID, Prestidge BR, Bagshaw MA, Cox RS. The importance of local control in the treatment of prostatic cancer. 7 UroH 992:147:917-21
25. Keyser D, Kupelian P, Zippe C, Klein E. Stage Tl-2 prostate cancer with pretreatment PSA 10 ng/mL or less: radiotherapy or surgery [Abstract]. Int J Radiat Oncol Biol Phys 1996; 36:196
26. Kuban DA, El-Mahdi AM, Schellhammer PF. Potential benefit of improved local tumor control in patients with prostate carcinoma. Cancer 1995:75:2373-82
27. Kupelian PA, Katcher J, Levin HS, Klein EA. Stage Tl-2 prostate cancer: a multi-variate analysis of factors affecting biochemical and clinical failures after radical prostatectomy. IntJ Radiat Oncol Biol Phys 1997:37:1043-52
28. Lee RJ, Sause WT. Surgically staged patients with prostatic carcinoma treated with definitive radiotherapy - 15 years results. Urology 1994;43:640-4
29. Lim AJ, Brandon AH, Fiedler J, Brickman AL, Boyer CI, Raub WA et al. Quality of life: radical prostatectomy versus radiation therapy for prostate cancer. J Urol 1995; 154:1420-5
30. Martinez A, Stromberg J, Edmundson G, Gustafson G, Vicini F, Brabbins D. On-line conformai HDR dose escalation trial in prostate cancer [Abstract]. Radiother Oncol 1996; 39(suppl 1):S1
31. Mazeron JJ, Haddad E. Adénocarcinomes prostatiques localisés : résultats de la radiothérapie. Bull Cancer/Radiother 1993;80:193-202
32. Middleton RG, Thompson IM, Austenfeld MG, Cooner WH, Correa RJ, Gibbons RP et al. Prostate cancer clinical guidelines panel summary report on the management of clinically localized prostate cancer. J Urol 1995:154:2144-8
33. Mostofi FK, Sestehenn LA, Davis CJ. A pathologist's view of prostatic carcinoma. Proceedings of the American Society National Conference on Prostate Cancer. Cancer 1993;71(suppl): 906-32
34. Perez CA, Michalski J, Brown KC, Lockett MA. Nonrandomized evaluation of pelvic lymph node irradiation in localized carcinoma of the prostate. Int J Radiat Oncol Biol Phys 1996; 36:573-84
35. Pilepich MV, Asbell SO, Krall JM, Baerwald WH, Sause WT, Rubin P et al. Correlation of radiotherapeutic parameters and treatment related morbidity. Analysis of RTOG study 77-06. Int J Radiat Oncol Biol Phys 1987; 13:1007-12
36. Roach M, Meehan S, Weil M, Ryu J, Small EJ, Margolis LW et al. Radiotherapy (XRT) for high grade (HG) clinically localized adenocarcinoma of the prostate (CAP) [Abstract]. Proc Am Soc ClinOncol 1996;15:238
37. Roeske JC, Forman JD, Mesina CF, He T, Pelizzari CA, Fon-tenla E et al. Evaluation of changes in the size and location of the prostate, seminal vesicles, bladder and rectum during a course of external beam radiation therapy. Int J Radiat Oncol Biol Phys 1995;33:1321-9
38. Schultheiss TE, Lee WR, Hunt MA, Hanlon AL, Peter RS, Hanks GE. Late GI and GU complications in the treatment of prostate cancer. Ira J Radiat Oncol Biol Phys 1997;37:3-11
39. Seymore CH, El-Mahdi AM, Schellhammer PF. The effect of prior transurethral resection of the prostate on post radiation urethral strictures and bladder neck contractures. Int J Radiat Oncol Biol Phys 1986; 12:1597-600
40. Shrader-Bogen CL, Kjelberg JL, Me Pherson CP, Murray C. Quality of life and treatment outcomes. Prostate carcinoma patients' perspectives after prostatectomy or radiation therapy. Cancer 1997;79:1977-86
41. Small EJ. Prostate cancer. Curr Opin Oncol 1997;9:277-86
42. Stock RG, Stone NN, lannuzzi C. Sexual potency following interactive ultrasound-guided brachytherapy for prostate cancer. Int J Radiat Oncol Biol Phys 1996;35:267-72
43. Stromberg J, Martinez A, Gonzalez J, Edmundson G, Ohanian N, Vicini F et al. Ultrasound-guided high dose rate conformai brachytherapy boost in prostate cancer: treatment description and preliminary results of a phase I/II clinical trial. Int J Radiat Oncol Biol Phys 1995;33:161-71
44. Wachter T, Peneau M, Sabattier R, Breteau N. Local control after brachytherapy for localized prostatic carcinomas [Abstract]. Radiother Oncol 1996;39(suppll):S2
45. Zagars OK, Pollack A, von Eschenbach AC. Prostate cancer and radiation therapy. The message conveyed by serum prostatespecific antigen. Int J Radiat Oncol Biol Phys 1995;39:23-35
46. Zelefsky MJ, Leibel SA, Burman CM, Kutcher GJ, Harrison A, Happersett L et al. Neoadjuvant hormonal therapy improves the therapeutic ratio in patients with bulky prostatic cancer treated with three-dimensional conformai radiation therapy. Int J Radiat Oncol Biol Phys 1994;29:755-61
47. Zelefsky MJ, Leibel SA, Kutcher GJ, Kelson S, Ling CC, Fuks Z. The feasibility of dose escalation with three-dimensional conformai radiotherapy in patients with prostatic carcinoma. Cancer J Sci Am 1995;1:142-50
48. Zelefsky MJ, Happersett L, Leibel SA, Burman CM, Schwanz L, Dicker AP et al. The effect of treatment positionning on normal tissue dose in patients with prostate cancer treated with three-dimensional conformai radiotherapy. Int J Radiat Oncol Biol Phys 1997;37:13-9
49. Zinreich ES, Derogatis LR, Herpst J, Auvil G, Piantadosi S, Order SE. Pre- and post-treatment evaluation of sexual function in patients with adenocarcinoma of the prostate. Int J Radiat Oncol Biol Phys 1990;19:729-32